Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Total Valuation
Nurix Therapeutics has a market cap or net worth of $671.64M. The enterprise value is $767.96M.
Market Cap$671.64M
Enterprise Value$767.96M
Share Statistics
Nurix Therapeutics has 76.24M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding76.24M
Owened by Insiders4.87%
Owened by Instutions6.13%
Financial Efficiency
Nurix Therapeutics’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -36.69%.
Return on Equity (ROE)-36.73%
Return on Assets (ROA)-28.92%
Return on Invested Capital (ROIC)-36.69%
Return on Capital Employed (ROCE)-37.15%
Revenue Per Employee$190,730.769
Profits Per Employee-$676,814.685
Employee Count286
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nurix Therapeutics is -7.67. Nurix Therapeutics’s PEG ratio is -0.88.
PE Ratio-7.67
PS Ratio27.21
PB Ratio2.82
Price to Fair Value2.82
Price to FCF-8.16
Price to Operating Cash Flow-8.60
PEG Ratio-0.88
Income Statement
In the last 12 months, Nurix Therapeutics had revenue of $54.55M and earned -$193.57M in profits. Earnings per share was -$2.89.
Revenue$54.55M
Gross Profit$42.42M
Operating Income-$213.03M
Pretax Income-$193.30M
Net Income-$193.57M
EBITDA-196.60M
Earnings Per Share (EPS)-2.89
Cash Flow
In the last 12 months, operating cash flow was -$172.58M and capital expenditures -$9.27M, giving a free cash flow of -$181.86M billion.
Operating Cash Flow-$172.58M
Free Cash Flow-$181.86M
Free Cash Flow per Share-$2.39
Dividends & Yields
Nurix Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-12.25%
Earnings Yield-13.04%
Stock Price Statistics
Beta2.40
52-Week Price Change-40.88%
50-Day Moving Average14.45
200-Day Moving Average20.35
Relative Strength Index (RSI)23.27
Average Volume (3m)1.12M
Important Dates
Nurix Therapeutics upcoming earnings date is Jul 10, 2025, After Close.
Last Earnings DateApr 8, 2025
Next Earnings DateJul 10, 2025
Ex-Dividend Date―
Financial Position
Nurix Therapeutics as a current ratio of 6.46, with Debt / Equity ratio of 0.05
Current Ratio6.46
Quick Ratio6.46
Debt to Market Cap0.02
Net Debt to EBITDA0.38
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nurix Therapeutics has paid $270.00K in taxes.
Income Tax$270.00K
Effective Tax Rate-0.14%
Enterprise Valuation
Nurix Therapeutics EV to EBITDA ratio is -6.58, with an EV/FCF ratio of -7.71.
EV to Sales25.71
EV to EBITDA-6.58
EV to Free Cash Flow-7.71
EV to Operating Cash Flow-8.13
Balance Sheet
Nurix Therapeutics has $609.58M in cash and marketable securities with $28.30M in debt, giving a net cash position of -$581.28M billion.
Cash & Marketable Securities$609.58M
Total Debt$28.30M
Net Cash-$581.28M
Net Cash Per Share-$7.62
Tangible Book Value Per Share$7.85
Margins
Gross margin is 100.00%, with operating margin of -390.52%, and net profit margin of -354.85%.
Gross Margin100.00%
Operating Margin-390.52%
Pretax Margin-354.36%
Net Profit Margin-354.85%
EBITDA Margin-390.52%
EBIT Margin-390.52%
Analyst Forecast
The average price target for Nurix Therapeutics is $30.19, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.19
Price Target Upside230.31%
Analyst ConsensusStrong Buy
Analyst Count17
Revenue Growth Forecast-30.25%
EPS Growth Forecast-5.92%